Abstract
Studies show Barrett's esophagus prevalence increases with age, while mean length of Barrett's esophagus is unchanged. Few data are available about the relationship between age and length on the development of dysplasia. Our aim was to assess age and length as risk factors for dysplasia. Consecutive patients with Barrett's esophagus were enrolled in a multicenter studyestablishing a tissue bank of Barrett's esophagus patients 1994 and 1998. Demographics, length of Barrett's esophagus (centimeters), and histology were recorded. Risk factors for dysplasia were assessed, including patient age, gender, and length of Barrett's esophagus. Statistical analysis was performed comparing prevalence of dysplasia (which included the presence of any carcinoma and high- or low-grade dysplasia) to age and length. In all, 309 patients were studied [278 (90%) male and 31 (10%) female]: 5 had adenocarcinoma of the esophagus, 11 had high-grade dysplasia, and 29 had low-grade dysplasia. Patients with Barrett's esophagus without dysplasia were younger than those with dysplasia [62 ± 0.8 years vs 67 ± 1.7 years (mean ± SEM, P = 0.02)]. The risk of dysplasia increased by 3.3%/yr of age. Mean length of Barrett's esophagus in patients with Barrett's alone vs dysplasia was 4.0 ± 0.2 cm vs 5.4 ± 0.4 cm (P = 0.003). Patients with Barrett's esophagus length ≥3 cm had a significantly greater prevalence of dysplasia compared to length <3 cm (23% vs 9%, P = 0.0001). The risk of dysplasia increased by 14%/cm of increased length. Multivariate analysis showed age and length to be independent risk factors. In conclusions; prevalence of dysplasia is strongly associated with age and length of Barrett's esophagus. These preliminary results can be used to develop a strategy for screening/surveillance based on age and length of Barrett's epithelium.
Similar content being viewed by others
REFERENCES
Cameron AJ, Lomboy CT: Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103:1241, 1992
Sampliner RE: Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93:1028, 1998
Rustgi AK: Biomarkers for malignancy in the columnar-lined esophagus. Gastroenterol Clin North Am 26;599, 1997
Spechler SJ: Barrett's esophagus. Semin Gastrointest Dis 7:51, 1996
Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al: Observer variation in the diagnosis of dysplasia in barrett's esophagus. Hum Pathol 19:166–178, 1988
Spechler SJ: Complications of gastroesophageal reflux disease. In The Esophagus, 2nd ed, DO Castell (ed). Boston, Little Brown,p 533, 1995
Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313:857, 1985
Spechler SJ: The frequency of esophageal cancer in patients with Barrett's esophagus. Acta Endosc 22:541, 1992
Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92:212, 1997
O'Connor JB, Falk GW, Richter JE: The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94:2037–2042, 1999
Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D: The Development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 93:536–541, 1998
Provenzale D, Schmitt C, Wong JB: Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94:2043, 1999
Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M: Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 30:14, 1989
Streitz JM Jr, Ellis FH, Tilden RL, Erickson RV: Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 93:911, 1998
Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE: Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 92:2012–2016, 1997
Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH: Specialized Intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 116:277–285, 1999
Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, Reid BJ: Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus. Ann Intern Med132:612–620, 2000
Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM: Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc50:23, 1999
Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, Van Deventer G, DenBesten L, Rubin CE: Endoscopic Biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94:81–90, 1988
Sagan C, Flejou JF, Diebold MD, Potet F, Le Bodic MF: Reproducibility of histological criteria of dysplasia in Barretts mucosa. Gastroentrol Clin Biol 18:D31–D34, 1994 (in French)
Sampliner RE, Garewal HS, Fennerty MB, Aickin M:Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 35:93–96, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gopal, D.V., Lieberman, D.A., Magaret, N. et al. Risk Factors for Dysplasia in Patients with Barrett's Esophagus (BE): Results from a Multicenter Consortium. Dig Dis Sci 48, 1537–1541 (2003). https://doi.org/10.1023/A:1024715824149
Issue Date:
DOI: https://doi.org/10.1023/A:1024715824149